# Temporal trends in hospitalizations and 30-day mortality in older patients during the COVID pandemic from March 2020 to July 2021

- 3 Sara Garcia-Ptacek MD, PhD<sup>1,2\*</sup>, Hong Xu MD, PhD<sup>1\*</sup>, Martin Annetorp MD<sup>2</sup>, Viktoria Bäck
- 4 Jerlardtz MD<sup>3</sup>, Tommy Cederholm MD, PhD<sup>1,2</sup>, Malin Engström MD<sup>4</sup>, Miia Kivipelto MD,
- 5 PhD<sup>1,2</sup>, Lars Göran Lundberg MD<sup>5</sup>, Carina Metzner MD<sup>2</sup>, Maria Olsson MD<sup>6,7</sup>, Josefina
- 6 Skogö Nyvang MD, PhD<sup>8</sup>, Carina Sühl Öberg MD<sup>9</sup>, Elisabet Åkesson MD, PhD<sup>10,11</sup>, Dorota
- 7 Religa MD, PhD<sup>1,2</sup>, Maria Eriksdotter MD, PhD<sup>1,2</sup>
- 8
- <sup>9</sup> <sup>1</sup>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society,
- 10 Karolinska Institutet, Stockholm, Sweden
- <sup>2</sup>Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden
- <sup>3</sup>Department of Geriatric medicine, Jakobsbergsgeriatriken, Stockholm, Sweden
- <sup>4</sup>Department of Geriatric medicine, Sabbatsbergsgeriatriken, Stockholm, Sweden
- <sup>5</sup>Department of Geriatric medicine, Dalengeriatriken Aleris Närsjukvård AB, Stockholm,
- 15 Sweden
- <sup>6</sup>Department of Geriatric medicine, Capio geriatrik Löwet, Stockholm, Sweden
- <sup>7</sup>Department of Geriatric medicine, Capio geriatrik Sollentuna, Stockholm, Sweden
- <sup>8</sup>Department of Geriatric medicine, Capio Geriatrik Nacka AB, Nacka, Sweden
- <sup>9</sup>Department of Geriatric medicine, Handengeriatriken, Aleris Närsjukvård AB, Stockholm,
   Sweden
- <sup>21</sup><sup>10</sup>Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society,
- 22 Karolinska Institutet, Stockholm, Sweden
- <sup>23</sup> <sup>11</sup>R&D unit, Stockholms Sjukhem, Stockholm, Sweden
- 24
- 25 \*Contributed equally
- 26

# 27 Correspondence to:

- 28 Sara Garcia-Ptacek MD, PhD
- 29 Division of Clinical Geriatrics,
- 30 Department of Neurobiology, Care Sciences and Society,
- 31 Karolinska Institutet, NEO, Blickagången 16, 141 52, Huddinge, Stockholm
- 32 E-mail: <u>sara.garcia-ptacek@ki.se</u>
- 3334 Hong Xu, MD PhD
- 35 Division of Clinical Geriatrics,
- 36 Department of Neurobiology, Care Sciences and Society,
- 37 Karolinska Institutet, NEO, Blickagången 16, 141 52, Huddinge, Stockholm
- 38 E-mail: <u>hong.xu.2@ki.se</u>
- 39
- 40 Running Title: Temporal trends, geriatric care, COVID-19 and non-COVID patients
- 41

```
42 Word counts:
```

- 43 Abstract: 337; Text: 2990; References:30; Tables:2; Figures:3
- 44
- 45
- 46

It is made available under a CC-BY-NC-ND 4.0 International license .

# 47 KEY POINTS

48 Question: Multiple previous reports in different countries and settings have shown higher case

49 fatality ratio or hospitalized case fatality ratio for COVID-19 in the first wave compared to the

second wave of the pandemic. However, less is known about how the COVID-19 waves

51 specifically affected the care of geriatric patients, including those with conditions other than

52 COVID. .

53

**Findings:** The total number of hospitalizations was 5,320 for COVID-19 and 32,243 for non-COVID-cases. In COVID-patients, the 30-day mortality rate was highest at the beginning of the first wave (29% in March-April 2020), reached 17% at the second wave peak (November-December) followed by 11-13% in the third wave (March-July 2021). The mortality in non-COVID geriatric patients showed a similar trend, but of lower magnitude (5-10%). During the incidence peaks, COVID-19 hospitalizations displaced non-COVID geriatric patients.

60

61 Meaning: Hospital admissions and 30-day mortality after hospitalizations for COVID-19

62 increased in periods of high community transmission, albeit with decreasing mortality rates from

63 wave 1 to 3, with a possible vaccination effect in wave 3. Thus, the healthcare system could not

64 compensate for the high community spread of COVID-19 during the pandemic peaks, which also

65 led to displacing care for non-COVID geriatric patients. These results are important for planning

66 healthcare resources in future health emergencies.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 67 ABSTRACT

- 68 **Importance:** Previous reports have suggested reductions in mortality risk from COVID-19
- 69 throughout the first wave of the COVID-19 pandemic. Mortality changes later in the
- 70 pandemic and pandemic effects on other types of geriatric hospitalizations are less studied.
- 71 **Objectives:** To describe the changes in hospitalizations and 30-day mortality in Stockholm
- for patients 70+ receiving inpatient geriatric care for COVID-19 and other causes.
- 73 **Design:** Observational study. For patients 70 or older, we present the incidence of 30-day
- 74 mortality from COVID-19 in the Stockholm region, in relationship to geriatric
- hospitalizations and 30-day mortality after admission for COVID-19 and other causes.
- 76 Setting: Hospitalizations for patients 70+ from geriatric clinics in Stockholm, Sweden
- hospitalized for COVID-19 or other causes between March 2020 and July 31, 2021, wereincluded.
- 79 **Participants:** The total number of geriatric hospitalizations for patients 70+ was 5,320 for
- 80 COVID-19 and 32,243 for non-COVID-19 causes, corresponding to 4,565 individual
- 81 COVID-19 patients and 19,308 non-COVID-19 patients.
- 82 **Exposure(s):** The date of hospital admission to a geriatric clinic.
- 83 Main Outcome(s) and Measure(s): 30-day mortality after admission.
- **Results:** In patients with COVID-19, the 30-day mortality rate was highest at the beginning of
- the first wave (29% in March-April 2020), decreased as the first wave subsided (7% July-
- August), increased again in the second wave (17% November-December), but failed to
- 87 increase as much in the third wave (11-13% March-July 2021). In non-COVID-19 geriatric
- patients during the same period, the 30-day mortality presented a similar trend, but with a
- smaller magnitude of variation (5 to 10%). The number of persons 70 or older testing positive
- for COVID-19 in Stockholm reached two peaks in 2020 (April and December), fell in January
  2021 and then increased again in March-April 2021.
- 92 Conclusions and Relevance: During the first and second waves, hospital admissions and 30-93 day mortality after geriatric hospitalization for COVID-19 increased in periods of high 94 community transmission, although the mortality peak was lower in wave 2 than in wave 1. 95 The mortality for non-COVID geriatric cases was lower and more stable but also showed an 96 increase with the pandemic peaks.
- 97
- 98 Key words: COVID-19, geriatric, hospitalizations, 30-day mortality, displacing care
- 99 100
- 10
- 101

It is made available under a CC-BY-NC-ND 4.0 International license .

#### **INTRODUCTION** 102

During the first wave of the COVID-19 pandemic in Stockholm from March to July 2020, 103 mortality for COVID-19 patients hospitalized in geriatric clinics decreased over time.<sup>1</sup> It was 104 unclear at the time whether this was due to improved care or to patient selection of more 105

106 severe cases earlier in the pandemic due to higher community incidence and an overburdened

107 healthcare system. Our results from that first wave included only in-hospital mortality and did

108 not explore how care for conditions other than COVID-19 was impacted by the pandemic.

109 Age is among the strongest risk factors for COVID-19 and the infection fatality ratio after age

70 is substantial.<sup>2, 3</sup> Here, we present data on geriatric hospitalizations for COVID-19 and 110

other causes, including 30-day mortality from admission and compare these to the incidence 111

of COVID-19 and 30-day mortality from COVID-19 in the Stockholm region for persons 70+. 112

113 We aim to describe how COVID-19 peaks affected geriatric patients 70 and older hospitalized

both for COVID-19 and for other causes in Stockholm.<sup>4-7</sup> 114

115

In previous reports, COVID-19 mortality in hospitalized patients in Sweden increased with 116

each pandemic wave and decreased between pandemic peaks.<sup>8,9</sup> According to the Swedish 117

Board of Health and Welfare, 60-day mortality after admission with COVID-19 decreased 118

119 from a first-wave peak in March 2020 (25%) to a first nadir in August-September 2020 (10%),

then rose again but to lower levels as the second wave progressed to a peak in December 2020 120

(20%), decreasing steadily afterwards.<sup>10</sup> Decreasing mortality during the first pandemic wave was also observed in studies from the US,<sup>11</sup> with subsequent increases in mortality during 121

122

pandemic surges.<sup>12</sup> A Spanish study reported that COVID-19 patients in the first wave were 123 older, with more comorbidities and higher mortality than in the second wave.<sup>13</sup> However, 124

125 information is missing on mortality trends later in the pandemic, trends in older population

126 and in geriatric patients with diagnoses other than COVID-19.

127

The aim of this study is to describe the changes over time in 30 day-mortality after admission 128 of patients 70 years and older, hospitalized in 9 geriatric clinics in the Stockholm region from 129

March 2020 to July 2021. We describe 30-day mortality both for patients hospitalized for 130

COVID-19 and other causes over the three waves of the pandemic. Weekly hospitalizations 131

132 for COVID-19 and other causes are presented and compared to the average weekly

133 hospitalizations in the same geriatric clinics in 2019. These results are presented in the context

134 of COVID-19 incidence and 30-day mortality and weekly hospitalizations from any cause in

135 population 70 and over in the Stockholm region.

136

#### **METHODS** 137

#### 138 Study population

We identified all hospitalizations of patients 70 years and older who were admitted to nine 139 geriatric hospitals in Stockholm, Sweden, from March 6<sup>th</sup>, 2020, to July 31st, 2021. We 140 excluded hospitalizations with a duration less than 24 hours or with an admission date after 141 August 1<sup>st</sup>, 2021, to allow one month follow-up for mortality. A total of 5,320 hospitalizations 142 143 for COVID-19 were included, together with 32,243 hospitalizations with non-COVID-19 diagnoses during the same period (Figure 1). This corresponded to 4,565 individual COVID-144 145 19 patients and 19,308 non-COVID-19 patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 147 Exposure and Outcome

148 The study exposure was the hospital admission date (March  $1^{st}$ , 2020, to July  $31^{st}$ , 2021). The 149 study outcome was 30-day mortality from admission. Patients were censored at death, or the 150 end of follow-up (September 10th, 2021) whichever came first.

151

# 152 COVID-19 diagnosis and covariates

The diagnosis of COVID-19 followed clinical practice and was based on a positive reverse 153 154 transcriptase-polymerase chain reaction (RT-PCR) analysis from nasopharyngeal swabs or, in case of a negative RT-PCR, typical clinical picture (including a consultation with a specialist 155 in infectious diseases) and a CT scan with typical COVID-19 findings. All hospitalizations 156 were included, and patients could have multiple hospitalizations. Hospitalizations for 157 diagnoses other than COVID-19 to the same nine geriatric hospitals in Stockholm during the 158 159 same period comprised the non-COVID group. We collected information on patient 160 demographics, initial vital signs, medications, diagnoses at discharge, and 30-day mortality through the hospital electronic health records. 30-day mortality was defined from the date of 161 admission to geriatrics. 162

admission to ger

163

# 164 COVID-19 incidence and mortality in the population 70 years and older in Stockholm

165 Information on confirmed cases with COVID-19 and mortality data in the population 70 and

over in Stockholm was provided by the Swedish Board of Health and Welfare for research

167 purposes (<u>www.socialstyrelsen.se</u>). Incidence data represents detected COVID-19 infections.

168 Thirty-day mortality corresponds to deaths where COVID-19 was the main cause of death

169 within 30 days of a positive test for persons 70 and over in the Stockholm region. Weekly

170 hospitalizations for any cause in this population were also included as reference.

171

# 172 Weekly hospitalizations in 2019

173 For comparison, the average weekly hospitalizations registered in 2019 in the 9 geriatric

clinics was presented. This was calculated by adding the total number of hospitalizations from
all clinics (30,969) and dividing by 52 calendar weeks resulting in an average of 596 new

- 176 hospitalizations per week.
- 177

# 178 Analysis

Summary statistics are displayed as mean ± standard deviation (SD) or median (interquartile
 range, IQR) or proportions.

181 30-day mortality rate is graphically presented in relationship to number of new admissions per

182 week and COVID-19 incidence and mortality in the Stockholm region. Via logistic regression

183 models, we assessed the effect of admission date on 30-day mortality, adjusted by age, sex,

- and medical treatment. Results were reported as odds ratios (OR) and 95% confidence
- interval (CI). Mortality rates were also compared against non-COVID-19 patients admitted to
- 186 the same geriatric clinics during the same period.
- 187 All analyses were performed using R (https://www.r-project.org) and Stata version 17.0
- 188 (StataCorp, College Station, TX).
- 189

It is made available under a CC-BY-NC-ND 4.0 International license .

### 190 Ethical statement

191 The Swedish Ethical Review Authority approved the study (Dnr 2020-02146, and 2020-192 03345).

193

# 194 **RESULTS**

# 195 Characteristics and treatments at admission

Among the hospitalizations due to COVID-19, 87 % (4645 hospitalizations) had positive COVID-19 RT-PCR while 675 (13%) had a negative RT-PCR but fulfilled the clinical and radiological criteria for COVID-19. Patients hospitalized for COVID-19 had a median age of 84 (IQR 78-89) years, 53% were women and 6% of the patients had low saturation (<90%) at admission. The median duration of hospitalization was 9 days (IQR 6-13) (**Table 1**). The median age of geriatric hospitalizations for other (non-COVID-19) diagnoses was higher (85 IQR 79-90), and their hospital stays were shorter (6 days: IQR 4-9).

The total number of hospitalizations in the geriatric hospitals fell sharply at the beginning of the pandemic from a pre-pandemic weekly average of 596 in 2019. After this initial drop in

the first wave, geriatric hospitalizations rallied, averaging 507 hospitalizations per week but

206 without a sustained return to pre-pandemic levels. When COVID-19 cases increased, non-

207 COVID-19 cases decreased accordingly (Figure 2A; Supplemental table 1).

208

# 209 Thirty-day mortality

210 Thirty-day mortality was highest at the beginning of the first wave (29% in March-April 2020

for COVID-19; 10% for non-COVID-19), decreased as the first wave subsided (7% July-

August for COVID-19; 6% for non-COVID-19), and increased again for COVID cases in the

second wave (17% November-December for COVID; 7% for non-COVID). Thirty-day

mortality remained more stable in the third wave (11 to 13% March-July 2021 for COVID-19;

215 6% non-COVID-19) (**Table 1**).

Figure 2B shows the relationship between weekly COVID-19 hospital admissions to the nine geriatric hospitals and 30-day mortality. Mortality is lowest when few COVID-19 patients are

hospitalized. **Figure 2C** presents the same relationship but for other geriatric patients. The

lowest mortality rates appear in the interpandemic peaks, when COVID hospitalizations were

220 lowest and non-COVID hospitalizations were highest.

Figure 3 shows the relationship between total COVID-19 cases and deaths in the Stockholm

region and COVID-19 hospitalizations and deaths in the geriatric hospitals. The number of

hospitalizations and the 30-day mortality rates increased with each pandemic peak and

decreased between the peaks. The 30-day mortality rate after a positive test in Stockholm and

the 30-day mortality rate after admission in the geriatric hospitals followed the pandemic and

- hospitalization curves. The smaller increase in the third wave probably indicates a vaccination
- 227 effect.
- **Table 2** shows 30-day mortality risk from logistic regression, adjusted by age, sex, Charlson

229 Comorbidity Index (CCI) and treatment. Compared with patients admitted to geriatrics for

- 230 COVID-19 in November-December 2020, the risk of 30-day mortality was higher (OR 1.92,
- 231 95% CI 1.55-2.37) in March-April 2020, and lower in July August 2020 (OR 0.31, 0.15-0.66).
- A downward tendency appeared again in January-February 2021(OR 0.70, 0.54-0.91), March-
- 233 April 2021 (OR 0.72, 0.55-0.94) and May-June-July (OR 0.75, 0.49-1.13) (**Table 2**).
- 234

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 235 Thirty-day mortality in non-COVID-19 hospitalizations

Compared with hospitalizations in November-December 2020, hospitalizations in MarchApril 2020 had the highest mortality risk (OR 1.33; 95 CI 1.10-1.61), while hospitalizations
from September-October 2020 (OR 0.67; 95% CI 0.55-0.82), March-April 2021 (0.81; 95%
CI 0.67-0.99) and May-July 2021 (OR 0.82; 95% CI 0.69-0.98) presented lower risk, after
adjusting (Table 1, Figure 2).

241

## 242 **DISCUSSION**

Several important observations appear in this study of hospitalized geriatric patients in 243 Stockholm, Sweden. First, hospital admissions fell sharply at the beginning of the pandemic 244 245 and didn't reach pre-pandemic levels throughout the whole observation period. Longer hospital stays in COVID-19 patients could be one reason for this finding. The length of 246 hospitalization for COVID-19 patients was in line with previous international reports.<sup>11, 14</sup> A 247 reduction in elective procedures probably also contributed to the fall in admissions. The 248 higher care burden for COVID-19 patients, together with the time required to don and doff 249 250 protective equipment may have led to greater care burden and lower capacity to accept new 251 cases. Additionally, hip and other osteoporotic fractures might have decreased in the population 70 and older due to the recommendations for this age group to avoid social 252 contact.<sup>15</sup> Hospital admissions further decreased during the summer months: the receding 253 254 COVID-19 waves probably contributed to this reduction as did the customary reductions in 255 available beds due to staff vacation which occur every summer.

256

Care seeking behaviour and the capacity of the healthcare system to detect and manage other 257 diseases was affected during the pandemic: for example, the Swedish Stroke Register reports 258 a decrease in the number of detected strokes in 2020 and 2021 compared to 2019.<sup>16</sup>. The 259 Swedish registry for cognitive/dementia disorders reported a 30% reduction in diagnostic 260 261 work-up.<sup>17</sup> One US study included over 23 million emergency department (ED) visits for elderly Medicare beneficiaries, and compared hospital admission rate and changes in 30-day 262 mortality between identical periods in 2018-19 and 2019-20.<sup>18</sup> The drop in ED visits and 263 264 increase in admission rate didn't correlate with local COVID-19 incidence. Mortality risk after ED visits also increased. The drop in ED visits, together with increased admission rate 265 and mortality suggest that patients were avoiding seeking care, selecting for a sicker patient 266 population in the ED. Furthermore, the lack of correlation with COVID-19 incidence suggests 267 that patient behaviours (rather than hospital capacity) were responsible.<sup>18</sup> Another US study 268 found a decrease in ED visits for serious cardiovascular conditions early in the pandemic with 269 gradual recovery (until October 2020)<sup>19</sup>. The same drop in cardiovascular visits was seen in 270 Europe.<sup>20, 21</sup> In contrast to the US study we saw a drop in hospitalizations in our cohort but not 271 272 a complete recovery afterwards. We do not have data on ED visits so we cannot distinguish 273 between patient care-seeking behaviours and triage in the ED. As seen in figure 2A COVID-274 19 patients displaced other diagnoses from geriatric care. The supply of geriatric 275 hospitalizations in our cohort was inelastic, remained relatively stable during the pandemic and was lower than in 2019. 276

277

Second, 30-day mortality rose and fell with the pandemic waves. However, the peak mortality in geriatric clinics was higher in the first than in the second wave. This effect was more evident for COVID-19 patients but appeared also in non-COVID geriatric patients. Several studies, including our previous study, have noted a decrease in mortality throughout the first

It is made available under a CC-BY-NC-ND 4.0 International license .

wave of the pandemic<sup>22</sup><sup>1</sup>. A subsequent increase was observed again during the second wave in Sweden <sup>9, 23</sup>. One study included more than 30,000 COVID-19 patients (including those admitted to the ICU) hospitalized between March and December 2020 in Sweden and showed that the 60-day case fatality rate for hospitalized cases decreased in the first wave but increased again in the second wave<sup>9</sup>. This study noted that the average age and comorbidities for hospitalized patients increased in the second wave, although they adjusted for these and other factors.

289

COVID-19 incidence was more severely underreported in the first wave in Sweden than later 290 in the pandemic.<sup>23</sup> Some patients were treated in their nursing homes and never transferred to 291 hospital, and this could have the effect of lowering the average age and comorbidities in the 292 first wave but, interestingly, this change in average age is not present in our cohort. This may 293 294 be explained by the fact that most patients admitted to inpatient geriatric hospital care lived in 295 their own homes prior to admission. In this geriatric cohort, the proportion of patients presenting with oxygen saturation under 90% at baseline decreased from 8.9% in March-April 296 297 2020 to 2% in June, increasing again to 7.7% in December 2020. In our previous article we 298 showed that low oxygen saturation at baseline explained some, but not all, of the temporal trend in mortality observed during the first wave.<sup>1</sup> Triage was probably harsher in the first 299 300 wave leading to a sicker patient population and higher mortality. The alpha variant arrived in 301 Sweden in December 2020, too late to explain the increase in 30-day mortality. Improvements 302 in treatment may also explain a part of the reduction in mortality.

303

In an international context, studies from Africa<sup>24</sup>, Italy<sup>25</sup>, and Germany<sup>26</sup> showed a significant 304 difference in COVID-mortality between the first wave and the second wave. Our temporal 305 trend closely follows the German report, with high initial case fatal ratio, nadir in summer 306 307 2020 and subsequent increase in the second wave. In Germany, the first wave was smaller 308 and led to fewer hospitalizations than the second, while the peaks in hospitalizations between 309 the waves were more similar in Sweden. Despite this, the highest mortality in both studies was seen in the initial peak of the first wave<sup>26</sup>. Another study examined raw case fatality ratio 310 311 (CFR) in 53 countries or regions and showed decreased mortality in the second wave in 43 of them, including in Sweden.<sup>2</sup> 312

313

Third, vaccinations probably changed the association between incidence and mortality in the third wave and averted the increase in 30-day mortality that had been apparent with increasing hospitalizations in the previous waves. The COVID-19 vaccination campaign began at the end of December 2020 in nursing homes and its effects on mortality were felt already in March-April 2021, as also seen in our cohort.<sup>28</sup>

319

We cannot completely explain the changes in mortality. First, it should be noted that the 30-320 day mortality rate for COVID-19 patients reported in our study is based on a large cohort of 321 322 older people in geriatric clinics in Stockholm, excluding nursing home patients treated in place, mild cases treated at home or cases treated in ICU or infectious disease wards instead 323 of the geriatric clinics. Second, during the first wave of pandemic, the treatment and care of 324 325 COVID-19 patients underwent great changes 326 (https://www.internetmedicin.se/behandlingsoversikter/infektion/covid-19/), these and 327 improvements are likely to be part of the reason for the decline in mortality during the first 328 wave. In the second wave, the national guidelines for COVID-19 patients hospitalized in

It is made available under a CC-BY-NC-ND 4.0 International license .

Sweden didn't undergo major changes. In a previous report, we have shown that the prognosis of COVID-19 for the most frail during the first wave was ominous <sup>29</sup>. It is possible that the most vulnerable and frail died during the first wave and thus contributing to lower mortality during the second wave.

333

We believe that due to the inelasticity of hospitalizations, increasing COVID-19 admissions 334 during pandemic waves led to corresponding decreases in non-COVID admissions. This may 335 have led to more stringent selection of admissions, a sicker patient population and greater 336 overall mortality. Changes in treatment guidelines, particularly use of anticoagulants and 337 corticosteroids led to improvement in the outcome of patients with COVID-19<sup>30</sup>. However, 338 except for vaccines and the third wave, these changes were implemented relatively early in 339 the pandemic (before or during the summer of 2020) and cannot explain all the later changes 340 in mortality.<sup>30</sup> 341

342

## 343 Strengths and limitations:

344 In Sweden, geriatric hospitalizations are indicated on criteria of biological (and not chronological aging). Non-frail and non-comorbid older patients may have been hospitalized 345 346 in other clinics (eg. infectious diseases) and not included in our cohort. Nine out of eleven 347 existing geriatric clinics in Stockholm participated in the study. Living situation, 348 comorbidities and medications were obtained from electronic health records with imperfect 349 ascertainment. Medications were considered present if they were present or prescribed within 24h of hospitalization and would have included both newly prescribed medications and those 350 351 removed after admission. We did not have information on vaccination, which would have been useful for assessing the decline of mortality in the third wave of the pandemic. Strengths 352 of this study are the large geriatric cohort including nine out of eleven geriatric clinics in 353 354 Stockholm treating patients with COVID-19. Also novel is the analysis of geriatric 355 hospitalizations for other causes and the long study period including three pandemic waves 356 over a period of 17 months.

357

## 358 **Conclusion:**

Thirty-day mortality was highest at the peak of the first wave, decreased in the inter-wave 359 360 period and then increased again but to a lower peak in the second wave. The mortality increase of the third wave was probably averted by the vaccination campaign. Non-COVID 361 362 mortality showed a similar trend but with lower magnitude. During COVID-19 incidence 363 peaks, COVID-19 hospitalizations displaced non-COVID geriatric patients. Despite a massive 364 organizational effort and the individual effort and sacrifice of health care workers, the healthcare system could not compensate for high community spread of COVID-19 during the 365 pandemic peaks. Hospital admissions fell at the beginning of the pandemic and never returned 366 to pre-pandemic levels, probably reflecting the greater complexity of COVID-19 patients 367 compared to ordinary geriatric patients. The sustained fall in hospital admissions is 368 369 particularly worrisome considering the backlog of cancelled and deferred care caused by the pandemic. COVID-19 disproportionally affects geriatric patients, and the broader pandemic 370 371 has disrupted geriatric care.

372

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 374 ACKNOWLEDGEMENTS

375 Sara Garcia-Ptacek has received funding from the Swedish Stroke Association, the regional agreement on medical training and clinical research between the Stockholm County council 376 377 and the Karolinska Institutet (ALF) and FORTE (#2017-01646). Hong Xu by StratNeuro (the 378 Strategic Research Area Neuroscience-Karolinska Institutet, Umeå University and KTH) and 379 the Center for Innovative Medicine (CIMED). Maria Eriksdotter by the Swedish medical 380 research council grant (#2016-02317 and #2020-02014) and the regional agreement on 381 medical training and clinical research between the Stockholm County council and the 382 Karolinska Institutet (ALF), Dorota Religa by the Swedish Research Council (#2012-2291 and 2020-06101). The authors are grateful to the Swedish Board of Health and Welfare (Frida 383 384 Broström and Henrik Nordin) for providing epidemiological data on COVID-19 in the population 70 years and older in Stockholm. The authors appreciate covidxix.org for their 385 clear presentation of Swedish Covid-19 statistics and their help in finding relevant data for 386 387 this study.

388

## 389 DECLARATION OF INTERESTS

390 None of the authors declare any conflict of interest pertinent to the present work.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 392 **REFERENCES**

393	1. Xu H, Garcia-Ptacek S, Annetorp M, et al. Decreased Mortality Over Time During the
394	First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study. J
395	Am Med Dir Assoc. Aug 2021;22(8):1565-1573 e4. doi:10.1016/j.jamda.2021.06.005
396	2. Seoane B. A scaling approach to estimate the age-dependent COVID-19 infection
397	fatality ratio from incomplete data. PLoS One. 2021;16(2):e0246831.
398	doi:10.1371/journal.pone.0246831
399	3. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio
400	for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond
401	Princess cruise ship, February 2020. Euro Surveill. Mar 2020;25(12)doi:10.2807/1560-
402	7917.ES.2020.25.12.2000256
403	4. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with
404	Covid-19 - Preliminary Report. The New England journal of medicine. Jul 17
405	2020;doi:10.1056/NEJMoa2021436
406	5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 -
407	Final Report. The New England journal of medicine. Oct 8 2020;doi:10.1056/NEJMoa2007764
408	6. Paolisso P, Bergamaschi L, D'Angelo EC, et al. Preliminary Experience With Low
409	Molecular Weight Heparin Strategy in COVID-19 Patients. Frontiers in pharmacology. 2020;11:1124.
410	doi:10.3389/fphar.2020.01124
411	7. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a
412	randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England). May 16
413	2020;395(10236):1569-1578. doi:10.1016/s0140-6736(20)31022-9
414	8. Strålin K, Wahlström E, Walther S, et al. Mortality trends among hospitalised COVID-19
415	patients in Sweden: A nationwide observational cohort study. Lancet Reg Health Eur. May
416	2021;4:100054. doi:10.1016/j.lanepe.2021.100054
417	9. Strålin K, Wahlström E, Walther S, et al. Second wave mortality among patients
418	hospitalised for COVID-19 in Sweden: a nationwide observational cohort study. medRxiv.
419	2021:2021.03.29.21254557. doi:10.1101/2021.03.29.21254557
420	10. Welfare SBoHa. <i>Healthcare and Covid</i> . 2021. Accessed 2021-09-29.
421	https://www.socialstyrelsen.se/statistik-och-data/statistik/statistik-om-covid-19/statistik-om-
422	slutenvard-av-patienter-med-covid-19/
423	11. Nguyen JL, Benigno M, Malhotra D, et al. Hospitalization and mortality trends among
424	patients with confirmed COVID-19 in the United States, April through August 2020. Journal of Public
425	Health Research. 10/28 2021;doi:10.4081/jphr.2021.2244
426	12. Moon RC, Mackey RH, Cao Z, et al. Is COVID-19 Less Deadly Now? Trends of In-
427	Hospital Mortality Among Hospitalized COVID-19 Patients in the United States. <i>Clin Infect Dis</i> . Sep 17
428	2021;doi:10.1093/cid/ciab830
429	13. Aznar-Gimeno R, Pano-Pardo JR, Esteban LM, et al. Changes in severity, mortality, and
430	virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2. <i>Sci Rep</i> . Sep 22
431	2021;11(1):18844. doi:10.1038/s41598-021-98308-x
432	14. Vekaria B, Overton C, Wisniowski A, et al. Hospital length of stay for COVID-19 patients:
433	Data-driven methods for forward planning. BMC Infect Dis. Jul 22 2021;21(1):700.
434	doi:10.1186/s12879-021-06371-6
435	15. Rydberg EM, Moller M, Ekelund J, Wolf O, Wennergren D. Does the Covid-19
436	pandemic affect ankie fracture incidence? Moderate decrease in Sweden. Acta Orthop. Aug
437	2021;92(4):381-384. doi:10.1080/17453674.2021.1907517
438 430	10. Register 155. <i>COVID-19 report Stroke</i> . 2021:4-5. Accessed 2021-09-29.
439	nups.//www.nksstroke.org/sve/torskning-statistik-och-verksamnetsutveckling/rapporter/ovriga-
440	17 Support 2021 https://www.ucruuca/cuodom/om_cuodom/com_cuo
441 112	17. Svebeni Annuai report 2021 <u>https://www.ucruuse/sveueni/oni-sveueni/arsrapporter</u> .
742	

It is made available under a CC-BY-NC-ND 4.0 International license .

443 18. Smulowitz PB, O'Malley AJ, Khidir H, Zaborski L, McWilliams JM, Landon BE. National 444 Trends In ED Visits, Hospital Admissions, And Mortality For Medicare Patients During The COVID-19 445 Pandemic. Health Affairs. 2021/09/01 2021;40(9):1457-1464. doi:10.1377/hlthaff.2021.00561 446 Pines JM, Zocchi MS, Black BS, et al. The effect of the COVID-19 pandemic on 19. 447 emergency department visits for serious cardiovascular conditions. Am J Emerg Med. Sep 2021;47:42-51. doi:10.1016/j.ajem.2021.03.004 448 449 De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial 20. 450 infarction in Italy in the COVID-19 era. Eur Heart J. Jun 7 2020;41(22):2083-2088. 451 doi:10.1093/eurheartj/ehaa409 452 21. Sokolski M, Gajewski P, Zymlinski R, et al. Impact of Coronavirus Disease 2019 (COVID-453 19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. Am 454 J Med. Apr 2021;134(4):482-489. doi:10.1016/j.amjmed.2020.08.043 455 22. Strålin K, Wahlström E, Walther S, et al. Mortality trends among hospitalised COVID-19 456 patients in Sweden: A nationwide observational cohort study. The Lancet Regional Health – Europe. 457 2021;4doi:10.1016/j.lanepe.2021.100054 458 23. Statistics on hospitalizations of patients with Covid-19 (2021). 459 24. Salyer SJ, Maeda J, Sembuche S, et al. The first and second waves of the COVID-19 460 pandemic in Africa: a cross-sectional study. Lancet (London, England). Apr 3 2021;397(10281):1265-461 1275. doi:10.1016/s0140-6736(21)00632-2 462 Dorrucci M, Minelli G, Boros S, et al. Excess Mortality in Italy During the COVID-19 25. 463 Pandemic: Assessing the Differences Between the First and the Second Wave, Year 2020. Frontiers in 464 public health. 2021;9:669209. doi:10.3389/fpubh.2021.669209 465 Gessler N, Gunawardene MA, Wohlmuth P, et al. Clinical outcome, risk assessment, 26. 466 and seasonal variation in hospitalized COVID-19 patients-Results from the CORONA Germany study. 467 PloS one. 2021;16(6):e0252867. doi:10.1371/journal.pone.0252867 468 27. Fan G, Yang Z, Lin Q, Zhao S, Yang L, He D. Decreased Case Fatality Rate of COVID-19 in 469 the Second Wave: A study in 53 countries or regions. Transboundary and emerging diseases. Mar 470 2021;68(2):213-215. doi:10.1111/tbed.13819 471 28. Sweden PHAo. Vaccination coverage and reported cases (Vaccinationstäckning och 472 rapporterade sjukdomsfall). 2021. 2021-05-20. Accessed 2021-11-08. https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-473 474 visualisering/vaccinationsstatistik/statistik-for-vaccination-mot-covid-19/uppfoljning-av-475 vaccination/vaccinationstackning-och-rapporterade-sjukdomsfall/ 29. 476 Hägg S, Jylhävä J, Wang Y, et al. Age, Frailty, and Comorbidity as Prognostic Factors for 477 Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care. J Am Med Dir 478 Assoc. Nov 2020;21(11):1555-1559.e2. doi:10.1016/j.jamda.2020.08.014 479 30. "Swedish Society of Infectious disease specialists SHsaSfCM. National care program for 480 suspected or confirmed COVID-19 (Nationellt vårdprogram för misstänkt och bekräftad covid-19). 481 2021:28. Accessed 2021-11-23. https://infektion.net/nationellt-vardprogram-covid19/#

It is made available under a CC-BY-NC-ND 4.0 International license .

# Table 1. Hospitalizations for COVID-19 and other causes in patients 70 and over in geriatric clinics

	2020- 2021	2020	2020	2020	2020	2020	2021	2021	2021
	Overall	Mar-Apr	May- June	July-Aug	Sep-Oct	Nov-Dec	Jan-Feb	Mar-Apr	May- June- July
COVID-19									
N	5320	990	813	117	118	1329	838	870	245
Age, year	84.0	84.5	85.0	86.0	85.5	84.0	83.0	81.0	81.0
	(78.0,	(79.0,	(79.0,	(81.0,	(81.0,	(79.0,	(78.0,	(76.0,	(75.0,
	89.0)	90.0)	91.0)	90.0)	91.0)	89.0)	89.0)	86.0)	88.0)
Women	2822	535	442	63	70	723	429	436	124
	(53.0%)	(54.0%)	(54.4%)	(53.8%)	(59.3%)	(54.4%)	(51.2%)	(50.1%)	(50.6%)
ссі	2.0 (0.0,	2.0 (0.0,	2.0 (0.0,	1.0 (0.0,	1.0 (0.0,	2.0 (0.0,	2.0 (0.0,	2.0 (0.0,	2.0 (0.0,
	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)
Hypertension	1777	380	310	25	43	383	268	306	62
	(33.4%)	(38.4%)	(38.1%)	(21.4%)	(36.4%)	(28.8%)	(32.0%)	(35.2%)	(25.3%)
Diabetes	2014	344	287	33	32	510	331	367	110
	(37.9%)	(34.7%)	(35.3%)	(28.2%)	(27.1%)	(38.4%)	(39.5%)	(42.2%)	(44.9%)
Chronic heart	761	179	152	11	21	176	115	85	22
failure	(14.3%)	(18.1%)	(18.7%)	(9.4%)	(17.8%)	(13.2%)	(13.7%)	(9.8%)	(9.0%)
Myocardial Infarction	233 (4.4%)	43 (4.3%)	31 (3.8%)	1 (0.9%)	4 (3.4%)	57 (4.3%)	39 (4.7%)	44 (5.1%)	14 (5.7%)
Chronical pulmonary disease	709 (13.3%)	148 (14.9%)	108 (13.3%)	9 (7.7%)	20 (16.9%)	185 (13.9%)	114 (13.6%)	106 (12.2%)	19 (7.8%)
Asthma	185 (3.5%)	36 (3.6%)	24 (3.0%)	3 (2.6%)	8 (6.8%)	41 (3.1%)	28 (3.3%)	39 (4.5%)	6 (2.4%)
Cancer	331	74	49	16	10	84	41	42	15
	(6.2%)	(7.5%)	(6.0%)	(13.7%)	(8.5%)	(6.3%)	(4.9%)	(4.8%)	(6.1%)
Stroke	307 (5.8%)	66 (6.7%)	58 (7.1%)	4 (3.4%)	9 (7.6%)	79 (5.9%)	38 (4.5%)	39 (4.5%)	14 (5.7%)
Atrial	1061	217	195	25	26	273	151	139	35
fibrillation	(19.9%)	(21.9%)	(24.0%)	(21.4%)	(22.0%)	(20.5%)	(18.0%)	(16.0%)	(14.3%)
Initial S02<90%	342 (6.4%)	89 (9.0%)	39 (4.8%)	3 (2.6%)	7 (5.9%)	99 (7.4%)	50 (6.0%)	42 (4.8%)	13 (5.3%)
ACEI	1229	246	198	21	24	276	204	190	70
	(23.1%)	(24.8%)	(24.4%)	(17.9%)	(20.3%)	(20.8%)	(24.3%)	(21.8%)	(28.6%)
ARB	1462	251	209	32	40	378	243	248	61
	(27.5%)	(25.4%)	(25.7%)	(27.4%)	(33.9%)	(28.4%)	(29.0%)	(28.5%)	(24.9%)
β-blocker	2745	531	419	65	54	681	436	430	129
	(51.6%)	(53.6%)	(51.5%)	(55.6%)	(45.8%)	(51.2%)	(52.0%)	(49.4%)	(52.7%)
ССВ	1621	295	237	34	24	412	255	286	78
	(30.5%)	(29.8%)	(29.2%)	(29.1%)	(20.3%)	(31.0%)	(30.4%)	(32.9%)	(31.8%)
Diuretics	2819	563	449	66	74	672	453	410	132
	(53.0%)	(56.9%)	(55.2%)	(56.4%)	(62.7%)	(50.6%)	(54.1%)	(47.1%)	(53.9%)
Statins	2148	380	309	40	48	548	354	380	89
	(40.4%)	(38.4%)	(38.0%)	(34.2%)	(40.7%)	(41.2%)	(42.2%)	(43.7%)	(36.3%)
Warfarin	388 (7.3%)	85 (8.6%)	61 (7.5%)	15 (12.8%)	7 (5.9%)	93 (7.0%)	62 (7.4%)	48 (5.5%)	17 (6.9%)
LMWH	2732	410	427	39	59	772	417	509	99
	(51.4%)	(41.4%)	(52.5%)	(33.3%)	(50.0%)	(58.1%)	(49.8%)	(58.5%)	(40.4%)

It is made available under a CC-BY-NC-ND 4.0 International license .

NOAC	1745	262	285	41	34	429	315	287	92
	(32.8%)	(26.5%)	(35.1%)	(35.0%)	(28.8%)	(32.3%)	(37.6%)	(33.0%)	(37.6%)
Glucocorticoids	1492	151	148	23	31	465	250	338	86
	(28.0%)	(15.3%)	(18.2%)	(19.7%)	(26.3%)	(35.0%)	(29.8%)	(38.9%)	(35.1%)
Antibiotics	1798	369	252	41	41	426	280	288	101
	(33.8%)	(37.3%)	(31.0%)	(35.0%)	(34.7%)	(32.1%)	(33.4%)	(33.1%)	(41.2%)
Days of hospitalization	9.0 (6.0, 13.0)	9.0 (6.0, 14.0)	9.0 (6.0, 14.0)	9.0 (6.0, 13.0)	11.0 (8.0, 19.0)	9.0 (6.0, 14.0)	8.0 (6.0, 12.0)	7.0 (5.0, 11.0)	8.0 (5.0, 10.0)
30-day	910	282	134	8 (6.8%)	21	228	106	99	32
mortality	(17.1%)	(28.5%)	(16.5%)		(17.8%)	(17.2%)	(12.6%)	(11.4%)	(13.1%)
Non-COVID									
N	32243	3177	3198	4191	4736	2770	3217	4028	6926
Age, year	85.0	86.0	86.0	85.0	85.0	85.0	85.0	85.0	85.0
	(79.0,	(80.0,	(80.0,	(79.0,	(79.0,	(80.0,	(79.0,	(79.0,	(79.0,
	90.0)	91.0)	91.0)	90.0)	90.0)	90.0)	90.0)	90.0)	90.0)
Women	19336	1895	1900	2574	2822	1635	1907	2429	4174
	(60.0%)	(59.6%)	(59.4%)	(61.4%)	(59.6%)	(59.0%)	(59.3%)	(60.3%)	(60.3%)
ссі	1.0 (0.0,	2.0 (0.0,	1.0 (0.0,	1.0 (0.0,	1.0 (0.0,	1.0 (0.0,	1.0 (0.0,	1.0 (0.0,	1.0 (0.0,
	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)	3.0)
Hypertension	9804	1150	1050	1305	1388	817	930	1138	2026
	(30.4%)	(36.2%)	(32.8%)	(31.1%)	(29.3%)	(29.5%)	(28.9%)	(28.3%)	(29.3%)
Diabetes	9080	908	844	1174	1360	769	887	1147	1991
	(28.2%)	(28.6%)	(26.4%)	(28.0%)	(28.7%)	(27.8%)	(27.6%)	(28.5%)	(28.7%)
Chronic heart	5001	668	541	627	680	430	480	622	953
failure	(15.5%)	(21.0%)	(16.9%)	(15.0%)	(14.4%)	(15.5%)	(14.9%)	(15.4%)	(13.8%)
Myocardial	1206	160	123	163	162	102	103	140	253
Infarction	(3.7%)	(5.0%)	(3.8%)	(3.9%)	(3.4%)	(3.7%)	(3.2%)	(3.5%)	(3.7%)
Chronical pulmonary disease	3189 (9.9%)	447 (14.1%)	379 (11.9%)	417 (9.9%)	446 (9.4%)	225 (8.1%)	313 (9.7%)	345 (8.6%)	617 (8.9%)
Asthma	538	76	60	56	74	46	48	70	108
	(1.7%)	(2.4%)	(1.9%)	(1.3%)	(1.6%)	(1.7%)	(1.5%)	(1.7%)	(1.6%)
Cancer	2173	266	246	275	289	186	219	266	426
	(6.7%)	(8.4%)	(7.7%)	(6.6%)	(6.1%)	(6.7%)	(6.8%)	(6.6%)	(6.2%)
Stroke	2254	257	289	316	327	188	224	282	371
	(7.0%)	(8.1%)	(9.0%)	(7.5%)	(6.9%)	(6.8%)	(7.0%)	(7.0%)	(5.4%)
Atrial	6578	896	765	851	942	557	638	714	1215
fibrillation	(20.4%)	(28.2%)	(23.9%)	(20.3%)	(19.9%)	(20.1%)	(19.8%)	(17.7%)	(17.5%)
Initial S02<90%	991	135	100	116	153	90	87	134	176
	(3.1%)	(4.2%)	(3.1%)	(2.8%)	(3.2%)	(3.2%)	(2.7%)	(3.3%)	(2.5%)
ACEI	7445	745	772	924	1049	673	768	940	1574
	(23.1%)	(23.4%)	(24.1%)	(22.0%)	(22.1%)	(24.3%)	(23.9%)	(23.3%)	(22.7%)
ARB	8602	803	836	1120	1274	737	805	1084	1943
	(26.7%)	(25.3%)	(26.1%)	(26.7%)	(26.9%)	(26.6%)	(25.0%)	(26.9%)	(28.1%)
β -blocker	17298	1744	1720	2231	2515	1445	1691	2202	3750
	(53.6%)	(54.9%)	(53.8%)	(53.2%)	(53.1%)	(52.2%)	(52.6%)	(54.7%)	(54.1%)
ССВ	9828	947	955	1240	1404	847	1018	1245	2172
	(30.5%)	(29.8%)	(29.9%)	(29.6%)	(29.6%)	(30.6%)	(31.6%)	(30.9%)	(31.4%)
Diuretics	17667	1740	1746	2229	2562	1475	1745	2275	3895
	(54.8%)	(54.8%)	(54.6%)	(53.2%)	(54.1%)	(53.2%)	(54.2%)	(56.5%)	(56.2%)
Statins	12580	1181	1272	1541	1810	1077	1328	1569	2802
	(39.0%)	(37.2%)	(39.8%)	(36.8%)	(38.2%)	(38.9%)	(41.3%)	(39.0%)	(40.5%)

It is made available under a CC-BY-NC-ND 4.0 International license .

Warfarin	2440	282	252	302	361	188	283	312	460
	(7.6%)	(8.9%)	(7.9%)	(7.2%)	(7.6%)	(6.8%)	(8.8%)	(7.7%)	(6.6%)
LMWH	5960	622	598	786	798	584	643	783	1146
	(18.5%)	(19.6%)	(18.7%)	(18.8%)	(16.8%)	(21.1%)	(20.0%)	(19.4%)	(16.5%)
NOAC	9975	942	1012	1245	1463	846	959	1245	2263
	(30.9%)	(29.7%)	(31.6%)	(29.7%)	(30.9%)	(30.5%)	(29.8%)	(30.9%)	(32.7%)
Glucocorticoids	5426	585	515	675	802	439	521	669	1220
	(16.8%)	(18.4%)	(16.1%)	(16.1%)	(16.9%)	(15.8%)	(16.2%)	(16.6%)	(17.6%)
Antibiotics	11154	1071	1000	1360	1547	986	1111	1469	2610
	(34.6%)	(33.7%)	(31.3%)	(32.5%)	(32.7%)	(35.6%)	(34.5%)	(36.5%)	(37.7%)
Days of	6.0 (4.0,	6.0 (4.0,	7.0 (4.0,	7.0 (4.0,	6.0 (4.0,	7.0 (5.0,	7.0 (5.0,	7.0 (4.0,	6.0 (4.0,
hospitalization	9.0)	8.0)	9.0)	9.0)	9.0)	9.0)	9.0)	9.0)	8.0)
30-day	2022	309	199	263	225	193	209	231	393
mortality	(6.3%)	(9.7%)	(6.2%)	(6.3%)	(4.8%)	(7.0%)	(6.5%)	(5.7%)	(5.7%)

485

Abbreviations: S02<90% peripheral oxygen saturation under 90%; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin

receptor blockers; CCB, calcium channel blockers; LMWH, low-molecular-weight heparin; NOAC, Non-vitamin-K antagonist oral

486 487 anticoagulant. Days of hospitalization: median number of days hospitalized (interquartile range). 30-day mortality is calculated from 488 the date of hospitalization.

489

It is made available under a CC-BY-NC-ND 4.0 International license .

# Table 2 Odds ratios for 30-day mortality in geriatric patients with COVID-19 and other diagnoses throughout the pandemic.

	COVID-19		Non-COVID	
	OR	95%CI	OR	95%CI
Mar-Apr 2020	1.92***	1.55,2.37	1.33**	1.10,1.61
May-June 2020	0.91	0.72,1.17	0.85	0.69,1.05
July-Aug 2020	0.31**	0.15,0.66	0.90	0.74,1.09
Sep-Oct 2020	0.99	0.59,1.64	0.67***	0.55,0.82
Nov-Dec 2020	ref		ref	
Jan-Feb 2021	0.70**	0.54,0.91	0.93	0.76,1.14
Mar-Apr 2021	0.72*	0.55,0.94	0.81*	0.67,0.99
May-June-July 2021	0.75	0.49,1.13	0.82*	0.69,0.98
Age				
70-79	ref		ref	
80-89	2.05***	1.68,2.51	1.62***	1.42,1.85
90+	3.06***	2.45,3.82	2.42***	2.11,2.77
Women	0.63***	0.54,0.74	0.68***	0.62,0.75
CCI	1.16***	1.12,1.20	1.18***	1.16,1.21
ACEI	0.94	0.78,1.14	0.84**	0.75,0.94
ARB	0.84	0.70,1.01	0.72***	0.64,0.80
β-blocker	1.20*	1.02,1.41	1.25***	1.13,1.39
ССВ	0.80*	0.68,0.95	0.72***	0.65,0.80
Diuretics	1.32***	1.12,1.55	1.49***	1.34,1.65
Statins	0.70***	0.59,0.82	0.74***	0.66,0.82
Warfarin	1.15	0.87,1.52	1.06	0.91,1.25
LMWH	1.06	0.88,1.26	1.23***	1.10,1.38
NOAC	0.93	0.77,1.13	0.98	0.88,1.08
Glucocorticoids	1.22*	1.03,1.45	1.18**	1.05,1.33
Antibiotic	1.51***	1.29,1.75	1.27***	1.16,1.40

493

494 Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers;

495 LMWH, low-molecular-weight heparin; NOAC, Non-vitamin-K antagonist oral anticoagulant.

It is made available under a CC-BY-NC-ND 4.0 International license .





It is made available under a CC-BY-NC-ND 4.0 International license .

# Figure 2 Hospitalizations and mortality throughout the COVID-19 pandemic for persons aged 70 and above





It is made available under a CC-BY-NC-ND 4.0 International license .



# B) 30-day COVID-19 mortality in relationship to weekly hospitalizations in geriatric clinics in patients 70 and above

It is made available under a CC-BY-NC-ND 4.0 International license .





It is made available under a CC-BY-NC-ND 4.0 International license .





### eTable 1 COVID-19 cases, mortality and hospitalizations in Stockholm and in geriatric clinics for population 70 and above.

560

Week	COVID-19 positive cases in Stockholm	30-day COVID-19 mortality Stockholm	COVID-19 hospitalizations in Stockholm	Total hospitalizations in Stockholm	COVID-19 geriatric hospitalizations	30-day mortality after geriatric hospitalization for COVID-19	Other diagnoses, geriatric hospitalizations	30-day mortality after geriatric hospitalization, non-COVID-19	Total geriatric hospitalizations
March 1, 2020							28	3	28
March 2, 2020			11	2 718	6	0	642	53	648
March 9, 2020	40	Х	67	2 515	15	4	529	51	544
March 16, 2020	231	22	268	2 364	38	17	417	49	455
March 23, 2020	557	102	550	2 237	111	39	307	40	418
March 30, 2020	675	213	724	2 130	178	67	264	18	442
April 6, 2020	763	345	735	2 120	175	46	256	33	431
April 13, 2020	709	305	643	2 116	172	47	246	28	418
April 20, 2020	598	233	620	2 260	187	41	280	17	467
April 27, 2020	420	207	465	2 030	141	25	278	21	419
May 4, 2020	392	147	464	2 245	144	28	311	28	455
May 11, 2020	293	117	412	2 120	141	13	324	32	465
May 18, 2020	286	85	322	1 999	112	26	333	18	445
May 25, 2020	262	67	302	2 186	97	25	346	24	443
June 1, 2020	240	77	289	2 277	94	15	409	25	503
June 8, 2020	196	49	240	2 320	88	14	401	19	489
June 15, 2020	154	42	149	2 081	51	2	392	19	443
June 22, 2020	131	27	124	2 235	42	6	445	21	487
June 29, 2020	53	18	87	2 187	35	3	474	33	509
July 6, 2020	40	11	57	2 125	28	1	487	28	515

It is made available under a CC-BY-NC-ND 4.0 International license

July 13, 2020	31	7	44	2 018	12	1	469	26	481
July 20, 2020	35	7	38	2 010	10	1	471	28	481
July 27, 2020	18	4	37	2 078	12	0	464	50	476
August 3, 2020	27	5	29	2 136	12	1	468	26	480
August 10, 2020	19	х	21	2 145	9	х	476	31	485
August 17, 2020	12	5	17	2 336	6	0	494	29	500
August 24, 2020	9	х	11	2 453	4	0	494	19	498
August 31, 2020	15	х	19	2 420	3	0	455	23	458
September 7, 2020	6	Х	10	2 552	2	x	535	20	537
September 14, 2020	33	Х	16	2 567	1	0	542	35	543
September 21, 2020	55	Х	24	2 552	4	x	542	22	546
September 28, 2020	64	Х	25	2 673	6	0	567	21	573
October 5, 2020	74	10	59	2 726	11	1	565	28	576
October 12, 2020	93	Х	73	2 655	18	3	581	32	599
October 19, 2020	141	10	87	2 592	17	5	540	28	557
October 26, 2020	295	17	196	2 683	60	10	492	19	552
November 2, 2020	626	32	287	2 545	71	19	432	33	503
November 9, 2020	755	66	404	2 433	108	22	351	22	459
November 16, 2020	864	85	542	2 565	137	22	318	19	455

November 23, 2020	842	92	560	2 579	173	31	327	18	500
November 30, 2020	818	104	552	2 596	174	27	289	25	463
December 7, 2020	830	108	583	2 680	183	29	301	19	484
December 14, 2020	857	124	608	2 590	175	34	302	20	477
December 21, 2020	634	104	471	2 247	172	26	252	24	424
December 28, 2020	653	91	433	2 308	156	22	229	17	385
January 4, 2021	540	83	431	2 361	148	22	292	17	440
January 11, 2021	410	70	338	2 501	142	23	348	22	490
January 18, 2021	357	68	278	2 512	116	16	370	28	486
January 25, 2021	252	56	218	2 475	107	14	412	29	519
February 1, 2021	225	41	173	2 403	69	5	416	31	485
February 8, 2021	220	33	117	2 363	68	7	425	19	493
February 15, 2021	261	21	176	2 513	91	7	441	27	532
February 22, 2021	298	17	179	2 504	73	8	460	31	533
March 1, 2021	339	30	188	2 446	83	10	463	32	546
March 8, 2021	367	23	233	2 576	87	12	481	33	568
March 15, 2021	446	30	256	2 510	100	12	464	16	564
				·		·			

March 22, 2021	459	30	284	2 664	118	13	462	26	580
March 29, 2021	459	33	259	2 337	105	11	468	19	573
April 5, 2021	434	21	259	2 357	101	12	394	28	495
April 12, 2021	419	31	267	2 435	120	12	443	30	563
April 19, 2021	347	30	201	2 376	92	7	459	21	551
April 26, 2021	246	23	147	2 463	74	12	482	28	556
May 3, 2021	211	19	136	2 529	46	4	468	30	514
May 10, 2021	142	15	77	2 318	39	6	489	27	528
May 17, 2021	84	13	71	2 582	30	3	518	28	548
May 24, 2021	59	8	40	2 469	25	3	510	35	535
May 31, 2021	12	5	26	2 537	17	3	529	26	546
June 7, 2021	17	х	16	2 462	8	0	515	16	523
June 14, 2021	19	х	12	2 553	14	1	567	30	581
June 21, 2021	5	х	12	2 289	17	2	513	22	530
June 28, 2021	11	х	6	2 362	7	х	544	30	551
July 5, 2021	6	0	7	2 271	7	х	576	39	583
July 12, 2021	8	0	10	2 107	5	х	566	43	571
July 19, 2021	16	0	7	2 105	9	х	526	32	535
July 26, 2021	23	0	12	2 134	11	х	517	33	528

medRxiv preprint doi: https://doi.org/10.1101/2021.12.22.21268237; this version posted December 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .